BR0009758A - Vacina anti-hiv, processos de preparação de anticorpos policlonais, para evidenciação da presença da proteìna tat ou uma parte da proteìna tat em uma amostra biológica e de sìntese de uma variante tat e kit diagnóstico - Google Patents

Vacina anti-hiv, processos de preparação de anticorpos policlonais, para evidenciação da presença da proteìna tat ou uma parte da proteìna tat em uma amostra biológica e de sìntese de uma variante tat e kit diagnóstico

Info

Publication number
BR0009758A
BR0009758A BR0009758-6A BR0009758A BR0009758A BR 0009758 A BR0009758 A BR 0009758A BR 0009758 A BR0009758 A BR 0009758A BR 0009758 A BR0009758 A BR 0009758A
Authority
BR
Brazil
Prior art keywords
tat
tat protein
synthesis
protein
biological sample
Prior art date
Application number
BR0009758-6A
Other languages
English (en)
Inventor
Erwann Loret
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9904610A external-priority patent/FR2792204B1/fr
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Publication of BR0009758A publication Critical patent/BR0009758A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"VACINA ANTI-HIV, PROCESSOS DE PREPARAçãO DE ANTICORPOS POLICLONAIS, PARA EVIDENCIAçãO DA PRESENçA DA PROTEìNA TAT OU UMA PARTE DA PROTEìNA TAT EM UMA AMOSTRA BIOLóGICA E DE SìNTESE DE UMA VARIANTE TAT E KIT DIAGNóSTICO". A presente invenção tem por objeto uma vacina anti-HIV 1 compreendendo toda ou parte da proteína Tat de HIV assim como a identificação da referida proteína junto aos indivíduos infectados pelo HIV. Particularmente, a proteína Tat é a da variante HIV- 1 Oyi.
BR0009758-6A 1999-04-13 2000-04-12 Vacina anti-hiv, processos de preparação de anticorpos policlonais, para evidenciação da presença da proteìna tat ou uma parte da proteìna tat em uma amostra biológica e de sìntese de uma variante tat e kit diagnóstico BR0009758A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9904610A FR2792204B1 (fr) 1999-04-13 1999-04-13 Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1
FR9916633A FR2792206B1 (fr) 1999-04-13 1999-12-29 Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
PCT/FR2000/000938 WO2000061067A2 (fr) 1999-04-13 2000-04-12 Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1

Publications (1)

Publication Number Publication Date
BR0009758A true BR0009758A (pt) 2002-01-08

Family

ID=26234914

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009758-6A BR0009758A (pt) 1999-04-13 2000-04-12 Vacina anti-hiv, processos de preparação de anticorpos policlonais, para evidenciação da presença da proteìna tat ou uma parte da proteìna tat em uma amostra biológica e de sìntese de uma variante tat e kit diagnóstico

Country Status (20)

Country Link
US (1) US7087377B2 (pt)
EP (1) EP1169057B1 (pt)
JP (1) JP4860823B2 (pt)
KR (1) KR100725637B1 (pt)
AT (1) ATE280586T1 (pt)
AU (1) AU775560B2 (pt)
BR (1) BR0009758A (pt)
CA (1) CA2370563C (pt)
DE (1) DE60015312T2 (pt)
DK (1) DK1169057T3 (pt)
ES (1) ES2231178T3 (pt)
FR (1) FR2792206B1 (pt)
HK (1) HK1044463B (pt)
HU (1) HUP0200841A2 (pt)
IL (2) IL145884A0 (pt)
MX (1) MXPA01010482A (pt)
NO (1) NO326603B1 (pt)
PL (1) PL197666B1 (pt)
PT (1) PT1169057E (pt)
WO (1) WO2000061067A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100465589B1 (ko) * 2001-04-20 2005-01-13 허만욱 비만 억제 폴리펩타이드
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
ES2500265T3 (es) * 2008-04-22 2014-09-30 Université D'aix-Marseille Proteína Tat Oyi mutada para prevenir o tratar SIDA
US8530431B2 (en) * 2009-03-23 2013-09-10 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
WO2011128720A1 (en) * 2010-04-14 2011-10-20 Mymetics Corporation Trans-activator of transcription protein
WO2012170765A2 (en) 2011-06-10 2012-12-13 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
RU2653754C2 (ru) 2012-12-06 2018-05-14 Пин Фарма, Инк. Лечение воспалительных, аутоиммунных и нейродегенеративных нарушений иммуннодепрессивными полипетидами, являющимися производными тат
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
AU2014329393B2 (en) 2013-10-04 2020-04-30 Pin Pharma, Inc. Immunostimulatory HIV Tat derivative polypeptides for use in cancer treatment
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5019510A (en) 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
US5132205A (en) * 1988-10-07 1992-07-21 Eastman Kodak Company High ph extraction composition and its use to determine a chlamydial, gonococcal or herpes antigen
US5461029A (en) * 1992-04-24 1995-10-24 American Cyanamid Company Method of treating herpes viral infections using HBNF and MK proteins
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
PL322143A1 (en) * 1995-03-08 1998-01-05 Neovacs Non-topxic immunogenes originating frommretroviral regulator protein, antibodies as such, method of preparing them and pharmaceutic compositions containing them
DE19514089C2 (de) * 1995-04-13 1997-07-10 Deutsches Krebsforsch Nachweisverfahren für HIV-TAT
JPH10212300A (ja) * 1996-11-26 1998-08-11 Sankyo Co Ltd ペプチドワクチン
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1

Also Published As

Publication number Publication date
PL353033A1 (en) 2003-10-06
ES2231178T3 (es) 2005-05-16
NO20014841D0 (no) 2001-10-04
DK1169057T3 (da) 2005-03-07
IL145884A (en) 2007-09-20
AU775560B2 (en) 2004-08-05
JP2002541165A (ja) 2002-12-03
FR2792206B1 (fr) 2006-08-04
HUP0200841A2 (en) 2002-07-29
PT1169057E (pt) 2005-03-31
CA2370563C (fr) 2013-12-17
HK1044463B (zh) 2005-06-03
WO2000061067B1 (fr) 2001-05-10
US7087377B2 (en) 2006-08-08
KR100725637B1 (en) 2007-06-07
NO326603B1 (no) 2009-01-19
US20050106161A1 (en) 2005-05-19
HK1044463A1 (en) 2002-10-25
KR20020005675A (ko) 2002-01-17
AU3972400A (en) 2000-11-14
IL145884A0 (en) 2002-07-25
EP1169057B1 (fr) 2004-10-27
FR2792206A1 (fr) 2000-10-20
EP1169057A2 (fr) 2002-01-09
MXPA01010482A (es) 2002-09-18
DE60015312D1 (de) 2004-12-02
CA2370563A1 (fr) 2000-10-19
DE60015312T2 (de) 2006-02-09
NO20014841L (no) 2001-11-27
ATE280586T1 (de) 2004-11-15
WO2000061067A3 (fr) 2001-03-29
JP4860823B2 (ja) 2012-01-25
PL197666B1 (pl) 2008-04-30
WO2000061067A2 (fr) 2000-10-19

Similar Documents

Publication Publication Date Title
BR0009758A (pt) Vacina anti-hiv, processos de preparação de anticorpos policlonais, para evidenciação da presença da proteìna tat ou uma parte da proteìna tat em uma amostra biológica e de sìntese de uma variante tat e kit diagnóstico
BR0008741A (pt) Peptìdeo de hiv, antìgenos, composições de vacina, kit de imunoensaio e método de detecção de anticorpos induzidos por hiv
BR0114036A (pt) Peptìdeos de hiv, antìgenos, composições de vacina, kit de imunoensaio e um método para detectar anticorpos induzidos pelo hiv
BRPI0417243A (pt) produto para cuidado pessoal com indicador visual de vaginite
DE69737736D1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
WO2003000853A3 (en) Protein aggregation assays and uses thereof
KR900013979A (ko) 사람 유두종비루스형 16의 e7 단백질상의 면역원성 영역
BR9712289A (pt) Composições e métodos para o tratamento de infecções virais
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
KR910019641A (ko) 사람 유두종 바이러스(hpv) 18의 단백질상의 혈청 반응성 에피토프
FR2586428B1 (fr) Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
BR0114046A (pt) Peptìdeos reguladores e auxiliares de hiv, antìgenos, composições de vacinas, kit de imunoensaio e um método para detectar anticorpos induzidos por hiv
ATE159300T1 (de) Monoklonale antikörper gegen menschliches ige
BRPI0504117A (pt) epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
Yamada et al. Laboratory diagnosis of dengue virus infection by reverse transcriptase polymerase chain reaction (RT-PCR) and IgM-capture enzyme-linked immunosorbent assay (ELISA)
WO1997025071A3 (en) Immunoconjugate for the treatment of aids
BR0215306A (pt) Uso de deoxipeganina
WO2006088740A3 (en) Methods and compositions for impairing multiplication of hiv-1
HK1050728A1 (en) Compositions and methods for detecting treponema pallidum.
Conlon HIV infection presenting as Guillain-Barre syndrome in Lusaka, Zambia
ATE245661T1 (de) Natürliche menschliche igm antikörper
KR890002402A (ko) 인간의 유두종바이러스형 41, 이의 dna 및 이로부터 코드화된 단백질
BR0210875A (pt) Antìgenos de streptococcus do grupo b e fragmentos de dna correspondentes
ES2163411T3 (es) Metodo para la identificacion de individuos infectados con vih y supervision de su terapia.
Halassy et al. Comment on “Antivenom for European Vipera species envenoming”

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 37, 8O, 13, 24 E 25 DA LPI 9.279

B12B Appeal against refusal [chapter 12.2 patent gazette]